Loading...
Studies have indicated that oral antiviral agents against hepatitis B (HBV) are generally safe and effective for preventing mother-to-child transmission, especially in the setting of high baseline maternal viral loads; however, these studies were small and of low quality. Now, researchers have conducted a manufacturer-sponsored, open-label trial at several academic centers in China. A total of 200 HBV-infected pregnant women (age range, 20–35) positive for hepatitis B e antigen (HBeAg) and with baseline HBV DNA >200,000 IU/mL were randomized to usual care (control) or tenofovir disoproxil fumarate (TDF; 300 mg daily from 30 to 32 weeks' gestation until postpartum week 4). All infants received immunoprophylaxis shortly after birth. The prima…